Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Levi, T.T. Keller, E. Van Gorp, Ten Cate.
Infection and inflammation and the coagulation system.
Cardiovasc Res, 60 (2003), pp. 26-39
[2.]
H. Ten Cate.
Pathophysiology of disseminated intravascular coagulation in sepsis.
Crit Care Med, 28 (2000), pp. S9-S11
[3.]
M. Levi, E. De Jonge, T. Van der Poll.
Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation.
Crit Care Med, 29 (2001), pp. S90-S94
[4.]
J.L. Vincent, Q. Sun, M.J. Dubois.
Clinical trials of immunomodulatory therapies in severe sepsis and septic shock.
Clin Infect Dis, 34 (2002), pp. 1084-1093
[5.]
M.A. Matthay.
Severe sepsis. A new treatment with both anticoagulant and antiinflammatory properties.
N Engl J Med, 344 (2001), pp. 759-762
[6.]
K. Murakami, Ojakima K. Uchiba.
Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production.
Am J Physiol, 272 (1997), pp. 197-202
[7.]
B.W. Grinnell, D. Joyce.
Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis.
Crit Care Med, 29 (2001), pp. S53-S60
[8.]
S.T. Grey, A. Tsuchida, H. Hau.
Selective inhibitory effects of the anticoagualant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-, or phorbol ester.
J Inmunol, 153 (1994), pp. 3664-3672
[9.]
D.E. Joyce, L. Gelbert, A. Ciaccia.
Gene expresion profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis.
J Biol Chem, 276 (2001), pp. 11199-11203
[10.]
G.R. Bernard, J.L. Vincent, P.F. Laterre, S.P. LaRosa, J.F. Dhainaut, A. Lopez-rodriguez.
and the Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group. Efficacy and safety of recombinat human activated protein C for severe sepsis.
N Engl J Med, 344 (2001), pp. 699-709
[11.]
P. Barton, A.C. Kalil, S. Nadel, B. Goldstein, R. Okhuysen-Cawley, R.J. Brilli, et al.
Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
Pediatrics, 113 (2004), pp. 7-17
[12.]
M. Levi.
Pathogenesis and treatment of disseminated intravascular coagulation in the septic patient.
J Crit Care, 16 (2001), pp. 167-177
[13.]
M. Levi, E. De Jonge, T. Van der Poll, H. Ten Cate.
Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies.
Semin Thromb Hemost, 27 (2001), pp. 569-575
[14.]
J.D. Nielsen.
The effect of antithrombin on the systemic inflammatory response in disseminated intravascular coagulation.
Blood Coagul Fibrinolysis, 9 (1998), pp. S11-S15
[15.]
D.L. Hartman, G.R. Bernard, J.D. Helterbrand.
Recombinant human activated protein C (rhAPC) improves coagulation abnormalities associated with severe sepsis.
Intensive Care Med, 24 (1998), pp. S77
[16.]
G.R. Bernard, E.W. Ely, T.J. Wright, J. Fraiz, J.r. Stasek JE, J.A. Russell, et al.
Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.
Crit Care Med, 29 (2001), pp. 2051-2059
[17.]
U. Derhaschnig, R. Reiter, P. Knobl, M. Baumgartner, P. Keen, B. Jilma.
Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia.
Blood, 102 (2003), pp. 2093-2098
[18.]
J.F. Dhainaut, P.F. Laterre, J.M. Janes, G.R. Bernard, A. Artigas, J. Bakker.
and Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.
Intensive Care Med, 29 (2003), pp. 894-903
[19.]
G.R. Bernard, W.L. Macias, D.E. Joyce, M.D. Williams, J. Bailey, J.L. Vincent.
Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.
Crit Care, 7 (2003), pp. 155-163
[20.]
B.J. Manns, H. Lee, C.J. Doig, D. Johnson, C. Donaldson.
An economic evaluation of activated protein C treatment for severe sepsis.
N Engl J Med, 347 (2002), pp. 993-1000
[21.]
D.C. Angus.
Drotrecogin alfa (activated). A viewpoint.
Drugs, 62 (2002), pp. 631-632
[22.]
H.S. Warren, A.F. Suffredini, P.Q. Eichaker, R.S. Munford.
Risks and benefits of activated Protein C treatment for severe sepsis.
N Engl J Med, 347 (2002), pp. 1027-1030
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados